Abstract
Wnt/β-catenin signaling is a highly conserved pathway essential for cell development, proliferation, migration, polarity, and stem cell homeostasis. This pathway has also been implicated in tumor initiation and progression. Recent efforts have been made to develop therapies targeting Wnt/β-catenin signaling; however, the complexity of Wnt signaling has complicated their development. While targeting Wnt has potential beneficial effects, understanding when to activate or inhibit Wnt to impede cancer development and progression still needs to be elucidated. Conventionally, Wnt signaling activation has been associated with poor patient outcome; however, it was recently shown to enhance patient outcome in certain cancer subtypes. Wnt target therapy is still in early stages, and numerous clinical trials are investigating Wnt signaling modulators as potential treatments for cancer. There is still much to learn about Wnt signaling and its interactions with other pathways. The next essential step is to identify potential biomarkers to guide how to perturb Wnt signaling for the most effective clinical results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- APC:
-
Adenomatous Polyposis Coli
- CBP:
-
CREB-binding protein
- CK1:
-
Casein Kinase 1
- COSMIC:
-
Catalogue of somatic mutations in cancer
- CSC:
-
Cancer stem cell
- Dkk1:
-
Dickkopf1
- Dvl:
-
Disheveled
- EMT:
-
Epithelial-to-mesenchymal transition
- FAP:
-
Familial adenomatous polyposis
- FZD:
-
Frizzled
- FZD8CRD:
-
Fusion protein containing the Fc region IgG fused to the cysteine-rich domain of FZD8
- GSK3β:
-
Glycogen Synthase Kinase 3β
- HCC:
-
Hepatocellular carcinoma
- HNSCC:
-
Head and neck squamous cell carcinoma
- LGR 4–6:
-
Leucine-rich repeat containing G-protein receptors
- LRP5/6:
-
Lipoprotein receptor-related protein
- Prcn:
-
Porcupine
- SFRPs:
-
Secreted frizzled-related proteins
- TCF/LEF:
-
T-cell factor/lymphoid enhance-binding factor
- TNKS:
-
Tankyrase
- WIFs:
-
WNT inhibitory factors
References
Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–73.
de Lau W, Peng WC, Gros P, Clevers H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 2014;28(4):305–16.
Karimaian A, Majidinia M, Bannazadeh Baghi H, Yousefi B. The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: implications in cancer therapy. DNA Repair. 2017;51:14–9.
Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13(7):513–32.
Mohammed MK, Shao C, Wang J, Wei Q, Wang X, Collier Z, et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3(1):11–40.
Blagodatski A, Poteryaev D, Katanaev VL. Targeting the Wnt pathways for therapies. Mol Cell Ther. 2014;2:28.
Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11–26.
Prosperi JR, Luu HH, Goss KH. Dysregulation of the Wnt pathway in solid tumors. In: Goss KH, Kahn M, editors. Targeting the Wnt pathway in cancer. New York: Springer; 2011. p. 81–128. Available from: http://link.springer.com/chapter/10.1007/978-1-4419-8023-6_5.
Tran FH, Zheng JJ. Modulating the wnt signaling pathway with small molecules. Protein Sci. 2017;26(4):650–61.
Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (review). Int J Mol Med. 2017;40(3):587–606.
Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052.
Zhang X, Hao J. Development of anticancer agents targeting the Wnt/β-catenin signaling. Am J Cancer Res. 2015;5(8):2344–60.
Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (review). Int J Oncol. 2017;51(5):1357–69.
Duffy DJ, Krstic A, Schwarzl T, Halasz M, Iljin K, Fey D, et al. Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget. 2016;7(37):60310–31.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stefanski, C.D., Prosperi, J.R. (2019). Role of Wnt/β-Catenin Pathway in Cancer Signaling. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)